Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu časopisecké články, multicentrická studie
PubMed
26799234
DOI
10.1002/ajh.24305
Knihovny.cz E-zdroje
- MeSH
- dospělí MeSH
- folikulární lymfom diagnóza farmakoterapie mortalita MeSH
- kohortové studie MeSH
- lékové interakce MeSH
- lidé středního věku MeSH
- lidé MeSH
- metastázy nádorů MeSH
- mladý dospělý MeSH
- prognóza MeSH
- proporcionální rizikové modely MeSH
- protokoly protinádorové kombinované chemoterapie škodlivé účinky terapeutické užití MeSH
- randomizované kontrolované studie jako téma MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- staging nádorů MeSH
- statiny škodlivé účinky terapeutické užití MeSH
- stupeň nádoru MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- Názvy látek
- statiny MeSH
An adverse prognostic impact of statin use in lymphoma was first suspected from in vitro data showing an impairment of anti-CD20 antibody binding. However, further clinical studies suggested an improved outcome associated with their use in hematological malignancies. In particular, a survival benefit was reported for patients with follicular lymphoma on statins. Our objective was to assess the outcome of follicular lymphoma patients treated in the PRIMA study with immunochemotherapy according to the use of statins. Among the 1,217 patients enrolled in the PRIMA study, 1,135 were included in the present study. Concomitant treatments at registration were available for all patients. Among those 1,135 patients, 119 were on statins (10.5%) at diagnosis. Adverse events frequencies, event-free survival (EFS), time to next lymphoma treatment (TTNLT), time to next chemotherapy (TTNCT), and overall survival (OS) were evaluated according to the use of statins. The rates of overall and specific cardiovascular adverse events between the two groups of patients were comparable both during induction and maintenance. Outcome in terms of response rates or EFS, TTNLT, TTNCT, and OS were similar regardless of the use of statins (P = 0.57, P = 0.85, P = 0.30, and P = 0.43, respectively) in univariate analysis and after further adjustments for potential confounding factors in multivariate analysis. In conclusion, statin use does not impact the prognosis of patients with follicular lymphoma treated with immunochemotherapy.
Deparment of Biostatistics Lysarc Lyon France
Hematology Department Centre Hospitalier De La Roche Sur Yon France
Hematology Department Centre Hospitalier Pontchaillou Rennes France
Hematology Department CHU De Reims Reims France
Hematology Department Chulalongkorn University Bangkok Thailand
Hematology Department Cliniques Universitaires UCL Saint Luc Brussels Belgium
Hematology Department Concord Hospital Concord NSW Australia
Hematology Department Hôpital Lyon Sud and Université Claude Bernard Pierre Bénite France
Hematology Department Hospital Son Llàtzer Palma De Mallorca Spain
Hematology Department Institut Gustave Roussy Villejuif France
Hematology Department Institut Paoli Calmettes Marseille France
Hematology Department Polyclinique Bordeaux Nord Aquitaine Bordeaux France
Hematology Department Portuguese Institute of Oncology Lisbon Portugal
Hematology Department University Hospital Hradec Kràlové Prague Czech Republic
Citace poskytuje Crossref.org
